OXFORD, U.K. & FREDERICK, Md.--(BUSINESS WIRE)--PowderMed, Ltd., today announced that it will begin testing a DNA-based annual influenza vaccine in a U.S.-based Phase I clinical trial. The study will assess the efficacy of a trivalent influenza vaccine administered to healthy adults using PowderMed’s Particle Mediated Epidermal Delivery (PMED™), a needle-free injection device that fires gold particles coated with DNA (encoding influenza virus genes) at supersonic speed into the immune cells of the skin.
